ACC 2021 | HOST-EXAM: Clopidogrel vs ASA monotherapy post DAPT in PCI patients

Clopidogrel monotherapy after dual antiplatelet therapy (DAPT) was associated with reduced mortality, MI, stroke, and other events in patients receiving PCI compared against aspirin monotherapy (ASA).

ACC 2021 | HOST-EXAM: Clopidogrel vs AAS como monoterapia post DAPT en las angioplastias

This information was provided by the Korean HOST-EXAM study, presented at ACC 2021 scientific sessions, and simultaneously published in the Lancet.

Researchers followed patients for 2 years and observed consistent results across subgroups, regardless baseline and angiographic characteristics. 

Primary end point, a combination of all cause death, MI, stroke, BARC 3 bleeding or higher, at 24 months, occurred in 5.7% of patients randomized to clopidogrel vs 7.7% of patients randomized to ASA (HR 0.73; IC 95% 0.59 a 0.90).

According to authors, the benefits of clopidogrel were observed both in thrombotic and bleeding terms. However, a longer followup in other populations is necessary (the whole cohort was Korean) to be able to reach more definitive conclusions. 

Guidelines on both sides of the Atlantic recommend ASA at long term after coronary PCI, but these study outcomes challenge ASA.


Read also: ACC 2021 | RAPID-TnT: Usefulness of High-Sensitivity Ultra-Fast Troponin T.


The HOST-EXAM randomized 5530 patients from 37 centers in Korea. All patients were free of events (thrombotic or bleeding) were within 6 to 18 months after coronary PCI and had completed the indicated DAPT period.

At the moment of intervention, over half of patients presented stable angina, 19.4% non-STEMI and 17.2% STEMI.

These new and provocative data raise our expectations for longer followup and similar results across different populations. 

HOST-EXAM

Original Title: Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.

Reference: Bon-Kwon Koo et al. Presentado en el congreso de la ACC 2021 y publicado simultáneamente en Lancet. https://doi.org/10.1016/S0140-6736(21)01063-1.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

How real are the adverse effects of statins? Evidence from randomized clinical trials

The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information,...

Rolling Stone: Registry of Intravascular Lithotripsy vs Atherectomy Use in Complex Calcified Lesions

Severe coronary calcification represents one of the main challenges in performing percutaneous coronary intervention, both due to the higher risk of stent underexpansion and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...